ATOS
Price
$0.87
Change
+$0.09 (+11.54%)
Updated
Jun 2 closing price
Capitalization
100.38M
76 days until earnings call
ERNA
Price
$0.22
Change
-$0.00 (-0.00%)
Updated
Jun 2 closing price
Capitalization
13.66M
Interact to see
Advertisement

ATOS vs ERNA

Header iconATOS vs ERNA Comparison
Open Charts ATOS vs ERNABanner chart's image
Atossa Therapeutics
Price$0.87
Change+$0.09 (+11.54%)
Volume$888.44K
Capitalization100.38M
Ernexa Therapeutics
Price$0.22
Change-$0.00 (-0.00%)
Volume$645.14K
Capitalization13.66M
ATOS vs ERNA Comparison Chart
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. ERNA commentary
Jun 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and ERNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2025
Stock price -- (ATOS: $0.87 vs. ERNA: $0.22)
Brand notoriety: ATOS and ERNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 120% vs. ERNA: 257%
Market capitalization -- ATOS: $100.38M vs. ERNA: $13.66M
ATOS [@Biotechnology] is valued at $100.38M. ERNA’s [@Biotechnology] market capitalization is $13.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileERNA’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • ERNA’s FA Score: 0 green, 5 red.
According to our system of comparison, ATOS is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 5 TA indicator(s) are bullish while ERNA’s TA Score has 4 bullish TA indicator(s).

  • ATOS’s TA Score: 5 bullish, 5 bearish.
  • ERNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than ERNA.

Price Growth

ATOS (@Biotechnology) experienced а +4.22% price change this week, while ERNA (@Biotechnology) price change was -3.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.09%. For the same industry, the average monthly price growth was +1.10%, and the average quarterly price growth was -0.30%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

ERNA is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (+4.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($100M) has a higher market cap than ERNA($13.7M). ATOS YTD gains are higher at: -8.188 vs. ERNA (-25.510). ATOS has higher annual earnings (EBITDA): -29.46M vs. ERNA (-36.12M). ATOS has more cash in the bank: 74.8M vs. ERNA (1.73M). ATOS has less debt than ERNA: ATOS (0) vs ERNA (684K). ERNA has higher revenues than ATOS: ERNA (582K) vs ATOS (0).
ATOSERNAATOS / ERNA
Capitalization100M13.7M730%
EBITDA-29.46M-36.12M82%
Gain YTD-8.188-25.51032%
P/E RatioN/AN/A-
Revenue0582K-
Total Cash74.8M1.73M4,326%
Total Debt0684K-
FUNDAMENTALS RATINGS
ATOS vs ERNA: Fundamental Ratings
ATOS
ERNA
OUTLOOK RATING
1..100
602
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6465
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5034

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (28) in the Medical Specialties industry is somewhat better than the same rating for ERNA (61). This means that ATOS’s stock grew somewhat faster than ERNA’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ERNA (100). This means that ATOS’s stock grew similarly to ERNA’s over the last 12 months.

ATOS's SMR Rating (100) in the Medical Specialties industry is in the same range as ERNA (100). This means that ATOS’s stock grew similarly to ERNA’s over the last 12 months.

ATOS's Price Growth Rating (64) in the Medical Specialties industry is in the same range as ERNA (65). This means that ATOS’s stock grew similarly to ERNA’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as ERNA (100). This means that ATOS’s stock grew similarly to ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSERNA
RSI
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 14 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ECTM0.560.02
+3.93%
ECA Marcellus Trust I
MTUAY204.914.39
+2.19%
MTU Aero Engines AG
CYDY0.34N/A
+0.88%
CytoDyn Inc.
RDEIY10.390.08
+0.78%
Redeia Corporacion SA
LDNXF150.90-2.29
-1.49%
London Stock Exchange Ltd.

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
+0.46%
CGEN - ERNA
39%
Loosely correlated
+2.04%
MDGL - ERNA
36%
Loosely correlated
-0.94%
IBIO - ERNA
32%
Poorly correlated
+6.62%
SMMT - ERNA
31%
Poorly correlated
-2.69%
ATOS - ERNA
30%
Poorly correlated
+11.54%
More